| 李 嘉,苗昌荣,郑志君,马丽梅,王晓蕊,梁 栋.阿托伐他汀联合参松养心胶囊治疗老年心力衰竭患者临床疗效及安全性研究[J].,2018,(20):3997-4000 |
| 阿托伐他汀联合参松养心胶囊治疗老年心力衰竭患者临床疗效及安全性研究 |
| A Study on the Clinical Effect and Safety of Atorvastatin Combined with Shensongyangxin Capsule on the Elderly Patients with Heart Failure |
| 投稿时间：2018-04-14 修订日期：2018-05-10 |
| DOI：10.13241/j.cnki.pmb.2018.20.045 |
| 中文关键词: 阿托伐他汀 参松养心胶囊 老年心力衰竭 临床疗效 安全性 |
| 英文关键词: Atorvastatin Shensongyangxin Capsule Elderly Heart failure Clinical efficacy Safety |
| 基金项目:河北省科技厅科研基金项目(12277739) |
|
| 摘要点击次数: 341 |
| 全文下载次数: 147 |
| 中文摘要: |
| 摘要 目的：探讨阿托伐他汀联合参松养心胶囊对老年心力衰竭患者的临床疗效及安全性。方法：选取我院心血管内科治疗的老年慢性心力衰竭患者121例，按治疗药物不同分为两组，对照组46例采用西医常规治疗，研究组75例常规治疗基础上给予阿托伐他汀联合参松养心胶囊治疗，记录两组12个月后的临床疗效，治疗后3、6及12个月后的总胆固醇（Total cholesterol，TC）、甘油三酯（Triglyceride，TG）、高密度脂蛋白胆固醇（High density lipoprotein cholesterol，HDL-C）、低密度脂蛋白胆固醇（Low density lipoprotein cholesterol，LDL-C）水平的变化及不良反应的发生情况。结果：与治疗3个月时相比，两组治疗12个月时临床有效率均显著提高，研究组治疗6、12个月后临床有效率均显著高于对照组(85.33% vs. 76.09%, 88% vs. 80.43%，P＜0.05)。两组治疗后血清TC、TG、LDL-C水平逐步下降，血清HDL-C水平逐步上升，研究组治疗第12月后血清TC、TG及LDL-C水平较对照组显著降低(P＜0.05)，血清HDL-C水平较对照组明显升高(P＜0.05)。两组在1年观察期内均未见明显肝肾功能损伤及肌溶解，不良反应发生率比较差异无统计学意义(P＞0.05)。结论：长期使用阿托伐他汀联合参松养心胶囊治疗老年性心力衰竭的临床效果明显优于西医常规治疗，其可有效降低血脂水平，安全性高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effect and safety of atorvastatin combined with Shensongyangxin Capsule on the elderly patients with heart failure. Methods: 121 cases of elderly patients with chronic heart failure were selected and divided into two groups according to the different therapeutic agents, 46 cases in the control group were treated with routine treatment, 75 cases in the experiment group were treated with Atorvastatin combined with Shensongyangxin capsule, both groups were treated for 12 months. The clinical efficacy at 12 months after treatment and the changes of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) levels at 3, 6 and 12 months after treatment and the incidence of adverse reaction were compared between two groups. Results: Compared with those at 3 months after treatment, the clinical effective rate of both groups at 12 months after treatment were significantly improved, and the clinical effective rates of experimental group at 6 and 12 months after treatment were significantly higher than those of the control group(85.33% vs. 76.09%, 88% vs. 80.43%, P＜0.05). After treatment, the levels of serum TC, TG and LDL-C levels were gradually decreased, and the level of serum HDL-C increased gradually in the two groups, the serum TC, TG and LDL-C levels in the experiment group were significantly lower than those of the control group at 12 months after treatment(P<0.05); the serum HDL-C level was significantly higher than that of the control group(P<0.05); there was no significant hepatic and renal dysfunction and myolysis in the two groups during the observation period of one year, there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05). Conclusion: Atorvastatin combined with Shensong Yangxin Capsule is significantly better than the routine western medicine in the treatment of senile heart failure, which can effectively reduce the blood lipid levels with high safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
